Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin - PubMed (original) (raw)
Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin
B Falini et al. Lancet. 1992.
Abstract
In Hodgkin's disease, Hodgkin and Reed-Sternberg cells consistently express the antigen CD30. We investigated the possible therapeutic role of an immunotoxin prepared by covalent linking of an anti-CD30 monoclonal antibody (Ber-H2) to saporin (SO6), a type-1 ribosome-inactivating protein. The immunotoxin (0.8 mg/kg in one or two doses) was given to four patients with advanced refractory Hodgkin's disease. In three, there was rapid and substantial reduction in tumour mass (50% to greater than 75%). Clinical responses were transient (6-10 weeks). In-vivo binding of the immunotoxin to tumour cells was shown by immunohistology in two patients. Antibodies to both parts of the immunotoxin developed in all patients.
Similar articles
- Ber-H2 (anti-CD30)-saporin immunotoxin: a new tool for the treatment of Hodgkin's disease and CD30+ lymphoma: in vitro evaluation.
Tazzari PL, Bolognesi A, de Totero D, Falini B, Lemoli RM, Soria MR, Pileri S, Gobbi M, Stein H, Flenghi L, et al. Tazzari PL, et al. Br J Haematol. 1992 Jun;81(2):203-11. doi: 10.1111/j.1365-2141.1992.tb08208.x. Br J Haematol. 1992. PMID: 1322690 - Anti-CD30 (BER=H2) immunotoxins containing the type-1 ribosome-inactivating proteins momordin and PAP-S (pokeweed antiviral protein from seeds) display powerful antitumour activity against CD30+ tumour cells in vitro and in SCID mice.
Terenzi A, Bolognesi A, Pasqualucci L, Flenghi L, Pileri S, Stein H, Kadin M, Bigerna B, Polito L, Tazzari PL, Martelli MF, Stirpe F, Falini B. Terenzi A, et al. Br J Haematol. 1996 Mar;92(4):872-9. doi: 10.1046/j.1365-2141.1995.404942.x. Br J Haematol. 1996. PMID: 8616080 - Antitumor activity of anti-CD30 immunotoxin (Ber-H2/saporin) in vitro and in severe combined immunodeficiency disease mice xenografted with human CD30+ anaplastic large-cell lymphoma.
Pasqualucci L, Wasik M, Teicher BA, Flenghi L, Bolognesi A, Stirpe F, Polito L, Falini B, Kadin ME. Pasqualucci L, et al. Blood. 1995 Apr 15;85(8):2139-46. Blood. 1995. PMID: 7718885 - Hodgkin's disease. Future treatment strategies: fact or fiction?
Schnell R, Barth S, Diehl V, Engert A. Schnell R, et al. Baillieres Clin Haematol. 1996 Sep;9(3):573-93. doi: 10.1016/s0950-3536(96)80028-x. Baillieres Clin Haematol. 1996. PMID: 8922247 Review. - Bispecific monoclonal antibodies for the targeting of type I ribosome-inactivating proteins against hematological malignancies.
Ferrini S, Sforzini S, Canevari S. Ferrini S, et al. Methods Mol Biol. 2001;166:177-92. doi: 10.1385/1-59259-114-0:177. Methods Mol Biol. 2001. PMID: 11217367 Review. No abstract available.
Cited by
- A bioinspired pseudopeptide-based intracellular delivery platform enhances the cytotoxicity of a ribosome-inactivating protein through multiple death pathways.
Morrison G, Henry N, Kopytynski M, Chen R. Morrison G, et al. Biomater Sci. 2024 Sep 25;12(19):5010-5022. doi: 10.1039/d4bm00600c. Biomater Sci. 2024. PMID: 39177215 Free PMC article. - Advances in the treatment of Hodgkin's lymphoma (Review).
Che Y, Ding X, Xu L, Zhao J, Zhang X, Li N, Sun X. Che Y, et al. Int J Oncol. 2023 May;62(5):61. doi: 10.3892/ijo.2023.5509. Epub 2023 Apr 7. Int J Oncol. 2023. PMID: 37026506 Free PMC article. Review. - Tumor-specific intracellular delivery: peptide-guided transport of a catalytic toxin.
Allred CA, Gormley C, Venugopal I, Li S, McGuire MJ, Brown KC. Allred CA, et al. Commun Biol. 2023 Jan 17;6(1):60. doi: 10.1038/s42003-022-04385-7. Commun Biol. 2023. PMID: 36650239 Free PMC article. - Plant-Derived Type I Ribosome Inactivating Protein-Based Targeted Toxins: A Review of the Clinical Experience.
Flavell DJ, Flavell SU. Flavell DJ, et al. Toxins (Basel). 2022 Aug 18;14(8):563. doi: 10.3390/toxins14080563. Toxins (Basel). 2022. PMID: 36006226 Free PMC article. Review. - Comparison of CD3e Antibody and CD3e-sZAP Immunotoxin Treatment in Mice Identifies sZAP as the Main Driver of Vascular Leakage.
Kim S, Shukla RK, Kim E, Cressman SG, Yu H, Baek A, Choi H, Kim A, Sharma A, Wang Z, Huang CA, Reneau JC, Boyaka PN, Liyanage NPM, Kim S. Kim S, et al. Biomedicines. 2022 May 24;10(6):1221. doi: 10.3390/biomedicines10061221. Biomedicines. 2022. PMID: 35740248 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical